Related Experiment Video

Updated: May 26, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E

Qun Zhang1, Li Li1, Xiaoping Qian1

  • 1Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China.

Human Vaccines & Immunotherapeutics
|February 25, 2025
PubMed

Insights

Metastatic colorectal cancer (mCRC) with BRAFV600E mutation is challenging to treat. A combination therapy of immunotherapy, radiotherapy, and targeted therapy achieved a durable complete response in a patient with refractory mCRC.

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Metastatic colorectal cancer (mCRC) with BRAFV600E mutation presents a poor prognosis.
  • BRAFV600E mutations drive abnormal signaling, leading to drug resistance and impacting patient survival.
  • Treatment of advanced or refractory mCRC with BRAFV600E mutations remains a significant clinical challenge.

Purpose of the Study:

  • To report a case of successful treatment in a patient with refractory metastatic colorectal cancer (mCRC) harboring the BRAFV600E mutation.
  • To evaluate the efficacy of a combination therapy regimen in a challenging mCRC subtype.

Main Methods:

  • A patient with metastatic colorectal cancer (mCRC) and BRAFV600E mutation in primary and metastatic sites was treated.
  • The patient received a combination therapy including immunotherapy (tislelizumab), radiotherapy, and targeted therapy (fruquintinib) after second-line treatment failure.
  • Comprehensive imaging and tumor marker monitoring were employed for evaluation.

Main Results:

  • The patient achieved and maintained a complete response (CR) for over 12 months.
  • The combination therapy demonstrated significant efficacy in a patient with refractory BRAFV600E-mutated mCRC.
  • No adverse events were mentioned in the abstract.

Conclusions:

  • Combination therapy involving immunotherapy, radiotherapy, and targeted therapy can be effective for BRAFV600E-mutated metastatic colorectal cancer.
  • This approach offers a potential treatment strategy for patients with refractory mCRC and poor prognosis.
  • Further research is warranted to explore this combination therapy in a larger cohort.
Keywords:
BRAFV600E mutationColorectal cancerimmunotherapyradiotherapytargeted therapy

More Related Videos

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.2K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463